ADB-4en-PINACA explained

ADB-4en-PINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a reasonably potent cannabinoid agonist in vitro but has not been so widely sold as related compounds such as ADB-PINACA and MDMB-4en-PINACA.[1] [2] [3] [4]

Legality

In the United States, the DEA has temporarily placed ADB-4en-PINACA into Schedule I status starting on December 12th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file to permanent placement the temporary Schedule I order will expire on December 12th, 2025.[5]

See also

Notes and References

  1. Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, Fletcher D, Gilbert N, Persson M, Reid R, Semenova O, Al Teneiji F, Wu X, Dahlén J, NicDaéid N, Tarbah F, Sutcliffe OB, McKenzie C, Gréen H . 6 . The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons . Drug Testing and Analysis . 14 . 4 . 634–652 . April 2022 . 34811926 . 10.1002/dta.3203 . 244490343 . free .
  2. Pike E, Grafinger KE, Cannaert A, Ametovski A, Luo JL, Sparkes E, Cairns EA, Ellison R, Gerona R, Stove CP, Auwärter V, Banister SD . 6 . Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB1 receptors . Drug Testing and Analysis . 13 . 7 . 1383–1401 . July 2021 . 33787091 . 10.1002/dta.3037 .
  3. Grafinger KE, Cannaert A, Ametovski A, Sparkes E, Cairns E, Banister SD, Auwärter V, Stove CP . 6 . Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays-Part II: Structure activity relationship assessment via a β-arrestin recruitment assay . Drug Testing and Analysis . 13 . 7 . 1402–1411 . July 2021 . 33769699 . 10.1002/dta.3035 .
  4. Grafinger KE, Vandeputte MM, Cannaert A, Ametovski A, Sparkes E, Cairns E, Juchli PO, Haschimi B, Pulver B, Banister SD, Stove CP, Auwärter V . 6 . Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays . Drug Testing and Analysis . 13 . 7 . 1412–1429 . July 2021 . 33908179 . 10.1002/dta.3054 . free . 1854/LU-8720689 . free .
  5. Web site: Federal Register :: Request Access .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "ADB-4en-PINACA".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.